drugset / Trial / NCT03472027
Phase I Study of BCD-145 (Anti-CTLA-4) in Patients With Unresectable/Metastatic Melanoma
Non-randomizedSequentialOpen-labelTreatment
Summary
A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of BCD-145 (JSC BIOCAD, Russia) Monotherapy in Patients with Unresectable/Metastatic Melanoma.
Timeline
- Start
- 2017-10-02
- Primary completion
- 2018-09-11
- Completion
- 2018-12-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | nurulimab | Monoclonal antibody | — | Intravenous |